Formycon AG (CHIX:FYBD) ROCE %: -9.44% (As of Dec. 2025)


CHIX:FYBD Formycon AG CHIX:FYBD
64 GF Score
Price €63.30
GF Value €121.24
! 5 Warning Signs
View Full Analysis

What is Formycon AG ROCE %?

Formycon AG CHIX:FYBD 64 ROCE % is -9.44% as of Dec. 2025. GuruFocus rates CHIX:FYBD with a GF Score™ of 64/100 and a GF Value™ of €121.24. The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Formycon AG's annualized ROCE % for the quarter that ended in Dec. 2025 was -9.44%.

Formycon AG  (CHIX:FYBd) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Formycon AG ROCE % Related Terms

Formycon AG ROCE % Historical Data

* Premium members only.

The historical data trend for Formycon AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Formycon AG ROCE % Chart

Formycon AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -21.62 8.51 9.75 -18.37 -12.27

Formycon AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.96 -1.72 -33.11 -15.18 -9.44
CHIX:FYBD
64GF Score
Formycon AG CHIX:FYBD
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Formycon AG ROCE % Calculation

Formycon AG's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-87.375/( ( (771.715 - 33.893) + (739.527 - 53.56) )/ 2 )
=-87.375/( (737.822+685.967)/ 2 )
=-87.375/711.8945
=-12.27 %

Formycon AG's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-65.476/( ( (742.562 - 40.926) + (739.527 - 53.56) )/ 2 )
=-65.476/( ( 701.636 + 685.967 )/ 2 )
=-65.476/693.8015
=-9.44 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -9.44% mean?
Formycon AG (CHIX:FYBD) has a ROCE % of -9.44% as of Dec. 2025.
Is Formycon AG's ROCE % too high?
Formycon AG's current ROCE % is -9.44%. Overall, Formycon AG has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Formycon AG's ROCE % compare to VRTX and REGN?
Formycon AG's ROCE % of -9.44% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Formycon AG's current ROCE % is -9.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Formycon AG stock overvalued right now?
Formycon AG (CHIX:FYBD) has a current ROCE % of -9.44%. The stock's GF Value™ is €121.24, compared to a current price of €63.30 — trading 47.8% below its estimated fair value. The current ROCE % is -9.44%. Formycon AG's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Formycon AG (CHIX:FYBD), the current ROCE % is -9.44% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Formycon AG (CHIX:FYBD) Overvalued in 2026?

Based on GuruFocus' analysis, Formycon AG stock appears to be undervalued. The current stock price of €63.30 is trading 47.8% below its estimated GF Value™ of €121.24.

Key valuation signals for CHIX:FYBD:

  • ROCE %: -9.44%
  • GF Value™: €121.24 vs. price of €63.30 (47.8% below fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the CHIX:FYBD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Formycon AG Business Description

Address Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152
Formycon AG is an independent developer of high-quality biosimilars, which are follow-on products to biopharmaceutical drugs. The Company focuses on expanding and further developing its scalable biosimilar platform, which includes approved and pipeline products across ophthalmology, immunology, and immuno-oncology. Its key products include FYB201 (ranibizumab), FYB202 (ustekinumab), FYB203 (aflibercept), FYB206 (pembrolizumab), and FYB208 (dupilumab), along with additional biosimilar candidates in various stages of development. The Company generates maximum revenue from Switzerland.
64GF Score

Get the complete analysis for CHIX:FYBD

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€63.30
Price
€121.24
GF Value